Grave Signs in Breast Cancer

Clinical Features Indicating High-Risk Disease

Large primary tumors ≥5 cm represent locally advanced disease requiring comprehensive staging workup including chest CT, abdominal imaging, and bone scan, as recommended by the European Society for Medical Oncology 1, 2, 3
Stage III disease where initial surgical approach is unlikely to achieve negative margins or provide long-term local control, according to the National Comprehensive Cancer Network 4
Clinically positive axillary lymph nodes mandate full staging investigations and indicate higher risk of distant metastases, as stated by the European Society for Medical Oncology 1, 2, 3
Macrometastases in lymph nodes (>2 mm) versus micrometastases or isolated tumor cells indicate more advanced disease, as reported by the European Society for Medical Oncology 1, 2, 3
High histological grade tumors demonstrate more aggressive behavior, according to the European Society for Medical Oncology 1, 2, 3

Peritumoral vascular invasion indicates increased risk of metastatic spread, as stated by the European Society for Medical Oncology 3, 6
Positive or close surgical margins increase risk of local recurrence, according to the European Society for Medical Oncology 1, 2, 3
HER2 overexpression without treatment historically indicated poor prognosis, as reported by the European Society for Medical Oncology 1, 2, 3

Localized bone pain warrants bone scan evaluation, as recommended by the National Comprehensive Cancer Network 4
Pulmonary symptoms require chest diagnostic CT, according to the National Comprehensive Cancer Network 4
Abdominal symptoms or abnormal abdominal/pelvic examination necessitate abdominal imaging with CT or MRI, as stated by the National Comprehensive Cancer Network 4
Elevated alkaline phosphatase suggests possible bone or liver metastases and requires bone scan and abdominal imaging, as reported by the National Comprehensive Cancer Network and the European Society for Medical Oncology 4, 7, 8

Chest CT is required to evaluate for pulmonary metastases, as recommended by the European Society for Medical Oncology 1, 2, 3
Abdominal imaging (CT or MRI) is necessary to assess liver and other abdominal organs, according to the European Society for Medical Oncology 1, 2, 3
Bone scan or sodium fluoride PET/CT is required to detect skeletal metastases, as recommended by the National Comprehensive Cancer Network 4
FDG-PET/CT may be useful when conventional imaging is inconclusive or for locally advanced disease, as stated by the European Society for Medical Oncology and Praxis Medical Insights 1, 9
Cardiac function assessment (echocardiogram or MUGA scan) is mandatory before anthracyclines or trastuzumab, as recommended by the European Society for Medical Oncology and Praxis Medical Insights 1, 9